Home Politics Earmark for Hepatitis B Foundation

Earmark for Hepatitis B Foundation

The foundation received a Community Project Funding grant for its Center of Public Health Excellence

U.S. Rep. Brian Fitzpatrick (R-1st dist.) announced the Hepatitis B Foundation received a Community Project Funding grant for the Hepatitis B Foundation’s Center of Public Health Excellence. The CPF was introduced by Fitzpatrick into the FY2022 Consolidated Appropriations Act as a part of the Community Project Funding program.

The project was selected because it will allow the foundation to provide expert resources, training and technical assistance on how to prevent, treat and control Hepatitis B to state and local health departments, social service organizations and community health providers. Furthermore, the center will build public health infrastructure to decrease health disparities and improve health access and outcomes in “underserved, disparately impacted communities of color,” working toward the ultimate goal of Hepatitis B elimination.

“Each year, up to 40,000 Americans become newly infected with Hepatitis B, with thousands dying from this infection. With the elimination of Hepatitis B in sight, we must continue to prioritize funding to find more effective treatments and ultimately a cure for this disease,” Fitzpatrick said. “As a member of the Congressional Hepatitis Caucus, I am proud to have a trailblazer in Hepatitis B research right here in Bucks County, but moreover, I am proud to have supported their community project request for the Center of Public Health Excellence, which supports the World Health Organization’s goal of eliminating Hepatitis B by 2030.”

The Hepatitis B Foundation is a national nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by Hepatitis B worldwide. The foundation’s commitment includes funding focused research, promoting disease awareness, supporting immunization and treatment initiatives and serving as the primary source of information for patients and their families, the medical and scientific communities, and the general public.

Exit mobile version